Skip to main content

Table 2 Use of migraine preventive therapies (oral drugs and botulinum toxin) among triptan-treated migraineurs with unmet medical needs (UMN) (overall cohort and stratified for the average triptan dose units per month) in the first year of follow-up

From: A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years

  Overall UMN migraineurs Average triptan dose units per month in 1 year
4–9 10–14 > 14
pLF-EM pHF-EM pCM
  31,515 22,2796 5467 3252
Oral Preventive Therapies in the 1st year
 Treated with at least one drug (%) 21.3 18.8 25.2 32.8
  1 drug (% of treated subjects) 82.9 84.9 82.0 75.7
  2 drugs (% of treated subjects) 15.1 13.8 15.4 20.2
  3 drugs (% of treated subjects) 1.8 1.1 2.4 3.8
  4 drugs (% of treated subjects) 0.2 0,2 0,2 0,3
 Active substance:
  Amitriptyline (%) 9.4 8.5 11.1 13.0
  Topiramate (%) 6.3 5.0 8.5 12.0
  Propranolol (%) 3.3 2.8 4.1 5.3
  Atenolol (%) 2.7 2.6 2.5 4.1
  Valproic acid (%) 1.8 1.4 2.0 3.9
  Pizotifen (%) 1.0 0.8 1.2 2.4
  Metoprolol (%) 0.6 0.6 0.7 1.1
  Timolol (%) 0.3 0.3 0.3 0.3
Botulinum Toxin in the 1st year
 Treated (%) 0.3 0.2 0.5 1.0
  1. UMN Unmet medical need, pLF-EM Possible low frequency episodic migraine, pHF-EM Possible high frequency episodic migraine, pCM Possible chronic migraine
\